-
公开(公告)号:US10882835B2
公开(公告)日:2021-01-05
申请号:US16445768
申请日:2019-06-19
IPC分类号: C07D295/192 , C07D213/81 , C07D233/90 , C07D295/185 , C07D295/26 , C07D215/14 , C07C237/22 , A61K31/166 , A61K31/40 , A61K31/4453 , A61K31/454 , A61K31/4545 , A61K31/47 , A61K31/495 , A61K31/5375 , A61K31/54
摘要: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
-
公开(公告)号:US10882834B2
公开(公告)日:2021-01-05
申请号:US15023349
申请日:2014-09-18
发明人: Peter Wipf , Erin M. Skoda , Zhou Wang
IPC分类号: A61K31/495 , C07D295/185 , C07D295/192 , A61K45/06 , C07D295/26 , C07D213/70 , C07D333/16 , C07D261/08 , C07D317/54 , C07D413/12 , A61K31/4525 , A61K31/551 , A61K31/58 , A61K31/496
摘要: A compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: R20—(Z)b—(Y)c—(R21)a—X—R22—R23 wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; Z is alkanediyl, substituted alkanediyl, cycloalkanediyl, or substituted cycloalkanediyl; Y is S, O, or NR10, wherein R10 is H or alkyl; R21 is alkanediyl, substituted alkanediyl, cycloalkanediyl, substituted cycloalkanediyl, alkadienyl, substituted alkadienyl, alkatrienyl, substituted alkatrienyl; X is —C(=0)- or —S(=0)(=0)-; R22 is a moiety that includes at least one divalent amino radical; R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; a is 0 or 1; b is 0 or 1; and c is 0 or 1; provided that if X is —C(=0)- then Y is not S.
-
公开(公告)号:US20200270223A1
公开(公告)日:2020-08-27
申请号:US16717813
申请日:2019-12-17
发明人: Justin S. CISAR , Cheryl A. GRICE , Todd K. JONES , Micah J. NIPHAKIS , Jae Won CHANG , Kenneth M. LUM , Benjamin F. CRAVATT
IPC分类号: C07D295/205 , C07C271/12 , C07D317/46 , C07D317/58 , C07D231/12 , C07D231/16 , C07D231/56 , C07D241/04 , C07D471/04 , C07D471/10 , C07D261/08 , C07D487/04 , C07D263/32 , C07D205/04 , C07D491/107 , C07D207/14 , C07D271/06 , C07D307/79 , C07D405/14 , C07D215/42 , C07D213/40 , C07D295/26 , C07D213/55 , C07D401/04 , C07D407/06 , C07D413/06 , C07C271/10 , C07D207/09 , C07D213/38 , C07D215/46 , C07D401/10 , C07D403/10 , C07D413/10
摘要: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.
-
公开(公告)号:US20200055813A1
公开(公告)日:2020-02-20
申请号:US16372119
申请日:2019-04-01
发明人: Jingye Zhou , Xiao-Yi Xiao , Louis Plamondon , Diana K. Hunt , Roger B. Clark , Robert Zahler
IPC分类号: C07C233/57 , C07D207/06 , C07D311/08 , C07D295/12 , C07D207/09 , A61K45/06 , A61K31/65 , C07D413/12 , C07D333/38 , C07D333/34 , C07D295/26 , C07D295/15 , C07D295/088 , C07D277/56 , C07D261/20 , C07D261/18 , C07D257/04 , C07D249/04 , C07D239/42 , C07D233/61 , C07D231/56 , C07D231/14 , C07D231/12 , C07D213/82 , C07D213/81 , C07D213/74 , C07D211/76 , C07D211/60 , C07D209/94 , C07D207/34 , C07D207/16 , C07D207/14 , C07D207/12 , C07D207/10 , C07D207/08 , C07D205/04 , C07C311/21 , C07C311/08
摘要: The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.
-
公开(公告)号:US10519118B2
公开(公告)日:2019-12-31
申请号:US15952073
申请日:2018-04-12
IPC分类号: C07D249/06 , A61K31/495 , A61K31/41 , C07D401/12 , C07D403/12 , C07D491/107 , C07D471/10 , C07D498/08 , C07C309/30 , A61K9/00 , A61K31/496 , C07D239/26 , A61K31/506 , C07D295/192 , C07D279/12 , A61K31/54 , C07D205/04 , A61K31/397 , C07D295/26 , C07D215/54 , C07C53/18 , C07D231/12 , C07D263/32 , A61K31/541 , C07B59/00 , A61K31/4192 , A61K31/454 , C07D249/08 , A61K31/4196 , C07D211/66 , A61K31/445 , C07D239/42 , C07D413/12 , A61K31/5377 , A61K31/5383 , A61K31/435 , C07D401/04 , C07D487/04 , A61K31/4162 , C07D487/08 , A61K31/4995 , A61K31/551 , C07D237/08 , A61K31/501 , A61K9/16 , A61K9/48 , A61K45/06 , A61P29/00 , A61P35/00 , A61P35/02 , A61P43/00
摘要: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
-
公开(公告)号:US20190352267A1
公开(公告)日:2019-11-21
申请号:US16459754
申请日:2019-07-02
申请人: CYTOKINETICS, INC.
发明人: Bradley Paul Morgan , Alex Muci , Pu-Ping Lu , Erica Anne Kraynack , Todd Tochimoto , David J. Morgans, JR.
IPC分类号: C07D213/75 , C07D417/00 , C07D417/12 , C07D513/04 , C07D491/04 , C07D487/04 , C07D417/10 , C07D211/56 , C07D401/10 , C07D295/26 , C07D271/113 , C07D263/48 , C07D261/14 , C07D239/42 , C07D401/12
摘要: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
-
公开(公告)号:US10385023B2
公开(公告)日:2019-08-20
申请号:US16021418
申请日:2018-06-28
发明人: Bradley Paul Morgan , Alex Muci , Pu-Ping Lu , Erica Anne Kraynack , Todd Tochimoto , David J. Morgans, Jr.
IPC分类号: C07D213/75 , C07D417/00 , C07D401/10 , C07D417/10 , C07D211/56 , C07D261/14 , C07D491/04 , C07D513/04 , C07D487/04 , C07D401/12 , C07D417/12 , C07D239/42 , C07D263/48 , C07D295/26 , C07D271/113
摘要: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
-
公开(公告)号:US10221129B2
公开(公告)日:2019-03-05
申请号:US15565690
申请日:2016-04-22
发明人: John A. Bender , Robert G. Gentles , Annapurna Pendri , Alan Xiangdong Wang , Nicholas A. Meanwell , Brett R. Beno , Robert A. Fridell , Makonen Belema , Van N. Nguyen , Zhong Yang , Gan Wang , Selvakumar Kumaravel , Srinivasan Thangathirupathy , Rajesh Onkardas Bora , Shilpa Maheshwarappa Holehatti , Mallikarjuna Rao Mettu , Manoranjan Panda
IPC分类号: C07C307/06 , C07C307/10 , C07C311/08 , A61P31/18 , A61K31/65 , C07D215/12 , C07D215/38 , C07D217/08 , C07D217/22 , C07D231/12 , C07D231/56 , C07D233/64 , C07D333/72 , C07D235/08 , C07D241/04 , C07D417/12 , C07D417/14 , C07D249/12 , C07D471/04 , C07D261/08 , C07D263/32 , C07D205/04 , C07D207/325 , C07D277/28 , C07D498/04 , C07D209/08 , C07D277/62 , C07D209/30 , C07D209/32 , C07D209/86 , C07D295/185 , C07D211/96 , C07D295/26 , C07D213/42
摘要: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
-
公开(公告)号:US10214477B2
公开(公告)日:2019-02-26
申请号:US15497556
申请日:2017-04-26
申请人: Oryzon Genomics S.A.
发明人: Alberto Ortega Muñoz , Matthew Colin Thor Fyfe , Marc Martinell Pedemonte , Maria de los Àngeles Estiarte Martinez , Nuria Valls Vidal , Guido Kurz , Julio Cesar Castro Palomino Laria
IPC分类号: C07C211/36 , C07D213/74 , C07C271/24 , C07C275/26 , C07D231/12 , C07D207/14 , C07D277/28 , C07D295/096 , C07D295/135 , C07D295/26 , C07D213/30 , C07D213/38 , C07D307/52 , C07C311/08 , C07C311/21 , C07C215/46 , C07C217/54 , C07C209/28 , C07C211/38 , C07C269/00 , C07C273/18 , C07C211/40 , C07C213/00 , C07C215/64 , C07C217/74 , C07C273/00 , C07D213/57 , C07D213/73 , C07D231/56 , C07D333/20
摘要: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
-
公开(公告)号:US20180305316A1
公开(公告)日:2018-10-25
申请号:US16021418
申请日:2018-06-28
发明人: Bradley Paul Morgan , Alex Muci , Pu-Ping Lu , Erica Anne Kraynack , Todd Tochimoto , David J. Morgans, JR.
IPC分类号: C07D213/75 , C07D417/00 , C07D401/10 , C07D417/10 , C07D211/56 , C07D261/14 , C07D491/04 , C07D513/04 , C07D487/04 , C07D271/113 , C07D417/12 , C07D401/12 , C07D239/42 , C07D263/48 , C07D295/26
CPC分类号: C07D213/75 , C07D211/56 , C07D239/42 , C07D261/14 , C07D263/48 , C07D271/113 , C07D295/26 , C07D401/10 , C07D401/12 , C07D417/00 , C07D417/10 , C07D417/12 , C07D487/04 , C07D491/04 , C07D513/04
摘要: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
-
-
-
-
-
-
-
-
-